Literature DB >> 24860914

Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study.

O Ahlehoff1, G Gislason, M Lamberts, F Folke, J Lindhardsen, C T Larsen, C Torp-Pedersen, P R Hansen.   

Abstract

OBJECTIVES: Psoriasis is a chronic inflammatory disease that is associated with a prothrombotic state and cardiovascular disease, including atrial fibrillation and thromboembolism. We therefore evaluated the impact of psoriasis in patients with atrial fibrillation and the performance of the CHA2 DS2 VASc score in these patients. DESIGN, SETTING AND PARTICIPANTS: The study comprised all Danish patients hospitalized with nonvalvular atrial fibrillation in the period 1997-2011 (n = 99,357). Follow-up started 7 days from discharge and excluded subjects treated with anticoagulation. Poisson regression adjusted for CHA2 DS2 VASc score was used to estimate the incidence rate ratios and 95% confidence intervals. MAIN OUTCOME MEASURE: Hospitalization or death from thromboembolism.
RESULTS: Mean follow-up was 3.5, 3.1, and 2.8 years for patients with no psoriasis, mild psoriasis and severe psoriasis, respectively. Patients with psoriasis were younger compared to patients without psoriasis, but CHA2DS2VASc score did not differ between the three groups. Thromboembolism rates per 100 patient-years (95% confidence intervals) were 4.8 (4.7-4.9), 4.8 (4.2-5.4) and 6.1 (5.0-7.5) for patients with no psoriasis, mild psoriasis and severe psoriasis, respectively. Importantly, the observed thromboembolism rates in patients with severe psoriasis were markedly higher (2.6- to3.4-fold) than predicted by the CHA2 DS2 VASc score. Relative to no psoriasis, incidence rate ratios were 0.99 (0.87-1.11) and 1.27 (1.02-1.57) for mild and severe psoriasis, respectively. Correspondingly, incidence rate ratios for fatal stroke were 0.97 (0.80-1.12) and 1.51 (1.12-2.05).
CONCLUSIONS: In patients with nonvalvular atrial fibrillation not treated with oral anticoagulation, severe psoriasis was associated with increased risk of thromboembolism. In these patients, CHA2 DS2 VASc underestimated the risk of thromboembolism.
© 2014 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  CHA2DS2VASc; atrial fibrillation; inflammation; psoriasis; stroke

Mesh:

Year:  2014        PMID: 24860914     DOI: 10.1111/joim.12272

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

1.  Psoriasis and Sleep Apnea: A Danish Nationwide Cohort Study.

Authors:  Alexander Egeberg; Usman Khalid; Gunnar Hilmar Gislason; Lotus Mallbris; Lone Skov; Peter Riis Hansen
Journal:  J Clin Sleep Med       Date:  2016-05-15       Impact factor: 4.062

2.  Antiplatelet and anticoagulant for prevention of reocclusion in patients with atrial fibrillation undergoing endovascular treatment for low extremity ischemia.

Authors:  Liangxi Yuan; Cheng Chen; Ziyuan Li; Guanglang Zhu; Junmin Bao; Zhiqing Zhao; Qingsheng Lu; Zaiping Jing
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells.

Authors:  Girish C Mohan; Huayi Zhang; Lei Bao; Benjamin Many; Lawrence S Chan
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 4.  Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.

Authors:  Stephen Chu-Sung Hu; Cheng-Che E Lan
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

5.  Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai.

Authors:  Feng-Di Liu; Rong Zhao; Xue-Mei Wang; Shuo Wang; Xiao-Lei Shen; Xiao-Xiao Tao; Bo Zheng; Jia-Li Peng; Hui Zhang; Ran Mo; Yan Tong; Wen-Ting Li; Xiao-Yan Feng; Ge-Fei Li; Liang Shu; Jian-Ren Liu
Journal:  Chronic Dis Transl Med       Date:  2016-01-08

6.  Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models.

Authors:  Jackelyn B Golden; Yunmei Wang; Yi Fritz; Doina Diaconu; Xiufen Zhang; Sara M Debanne; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  J Transl Med       Date:  2015-12-16       Impact factor: 5.531

Review 7.  The Predictive Role of Inflammatory Biomarkers in Atrial Fibrillation as Seen through Neutrophil-Lymphocyte Ratio Mirror.

Authors:  Feliciano Chanana Paquissi
Journal:  J Biomark       Date:  2016-07-03

8.  Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study.

Authors:  Tae-Min Rhee; Ji Hyun Lee; Eue-Keun Choi; Kyung-Do Han; HyunJung Lee; Chan Soon Park; Doyeon Hwang; So-Ryoung Lee; Woo-Hyun Lim; Si-Hyuck Kang; Myung-Jin Cha; Youngjin Cho; Il-Young Oh; Seil Oh
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

Review 9.  Potential Role of Atrial Myopathy in the Pathogenesis of Stroke in Rheumatoid Arthritis and Psoriasis: A Conceptual Framework and Implications for Prophylaxis.

Authors:  Milton Packer
Journal:  J Am Heart Assoc       Date:  2020-01-24       Impact factor: 5.501

10.  Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.

Authors:  Philip Mease; Christina Charles-Schoeman; Stanley Cohen; Lara Fallon; John Woolcott; Huifeng Yun; Joel Kremer; Jeffrey Greenberg; Wendi Malley; Alina Onofrei; Keith S Kanik; Daniela Graham; Cunshan Wang; Carol Connell; Hernan Valdez; Manfred Hauben; Eric Hung; Ann Madsen; Thomas V Jones; Jeffrey R Curtis
Journal:  Ann Rheum Dis       Date:  2020-08-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.